Lv4
590 积分 2022-09-14 加入
A Direct-to-Patient Digital Health Program for Lung Cancer Screening
3小时前
已完结
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study
7小时前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
8小时前
待确认
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
8小时前
已完结
Effectiveness of non-pharmacological interventions for relieving thirst in intensive care unit patients: A network meta-analysis
27天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2个月前
已完结
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
3个月前
已完结
First-Line Alectinib, Brigatinib, and Lorlatinib for Advanced ALK-Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis
3个月前
已完结
Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action
3个月前
已完结
Correction to “Cancer treatment and survivorship statistics, 2025”
3个月前
已完结
皖公网安备34019202002308
